  The wide spread of coronavirus disease 2019 (COVID-19) has declared a global
health emergency. As one of the most important targets for antibody and drug
developments, Spike RBD-ACE2 interface has received extensive attention. Here,
using molecular dynamics simulations, we explicitly evaluated the binding
energetic features of the RBD-ACE2 complex of both SARS-CoV and SARS-CoV-2 to
find the key residues. Although the overall ACE2-binding mode of the SARS-CoV-2
RBD is nearly identical to that of the SARS-CoV RBD, the difference in binding
affinity is as large as -16.35 kcal/mol. Energy decomposition analyses
identified three binding patches in the SARS-CoV-2 RBD and eleven key residues
(Phe486, Tyr505, Asn501, Tyr489, Gln493, Leu455 and etc) which are believed to
be the main targets for drug development. The dominating forces are from van
der Waals attractions and dehydration of these residues. It is also worth
mention that we found seven mutational sites (Lys417, Leu455, Ala475, Gly476,
Glu484, Gln498 and Val503) on SARS-CoV-2 which unexpectedly weakened the
RBD-ACE2 binding. Very interestingly, the most repulsive residue at the
RBD-ACE2 interface (E484), is found to be mutated in the latest UK variant,
B1.1.7, cause complete virus neutralization escapes from highly neutralizing
COVID-19 convalescent plasma. Our present results indicate that at least from
the energetic point of view such E484 mutation may have beneficial effects on
ACE2 binding. The present study provides a systematical understanding, from the
energetic point of view, of the binding features of SARS-CoV-2 RBD with ACE2
acceptor. We hope that the present findings of three binding patches, key
attracting residues and unexpected mutational sites can provide insights to the
design of SARS-CoV-2 drugs and identification of cross-active antibodies.
